1. Home
  2. KROS vs MPB Comparison

KROS vs MPB Comparison

Compare KROS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • MPB
  • Stock Information
  • Founded
  • KROS 2015
  • MPB 1868
  • Country
  • KROS United States
  • MPB United States
  • Employees
  • KROS N/A
  • MPB N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • MPB Major Banks
  • Sector
  • KROS Health Care
  • MPB Finance
  • Exchange
  • KROS Nasdaq
  • MPB Nasdaq
  • Market Cap
  • KROS 460.6M
  • MPB 525.0M
  • IPO Year
  • KROS 2020
  • MPB N/A
  • Fundamental
  • Price
  • KROS $11.00
  • MPB $29.19
  • Analyst Decision
  • KROS Buy
  • MPB Buy
  • Analyst Count
  • KROS 11
  • MPB 2
  • Target Price
  • KROS $45.33
  • MPB $36.00
  • AVG Volume (30 Days)
  • KROS 2.1M
  • MPB 71.0K
  • Earning Date
  • KROS 02-26-2025
  • MPB 01-22-2025
  • Dividend Yield
  • KROS N/A
  • MPB 2.74%
  • EPS Growth
  • KROS N/A
  • MPB 14.41
  • EPS
  • KROS N/A
  • MPB 2.91
  • Revenue
  • KROS $651,000.00
  • MPB $173,416,000.00
  • Revenue This Year
  • KROS $303.27
  • MPB N/A
  • Revenue Next Year
  • KROS N/A
  • MPB $19.26
  • P/E Ratio
  • KROS N/A
  • MPB $10.05
  • Revenue Growth
  • KROS 8037.50
  • MPB 4.93
  • 52 Week Low
  • KROS $9.78
  • MPB $19.20
  • 52 Week High
  • KROS $73.00
  • MPB $33.87
  • Technical
  • Relative Strength Index (RSI)
  • KROS 24.79
  • MPB 46.67
  • Support Level
  • KROS $11.04
  • MPB $30.02
  • Resistance Level
  • KROS $11.99
  • MPB $31.36
  • Average True Range (ATR)
  • KROS 0.60
  • MPB 0.75
  • MACD
  • KROS 1.20
  • MPB 0.16
  • Stochastic Oscillator
  • KROS 43.99
  • MPB 45.23

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

Share on Social Networks: